I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Lupus Nephritis

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Feb 7 / Roche and Genentech
Results from the REGENCY trial assessing efficacy and safety of obinutuzumab in active lupus nephritis
This is the first presentation of results from the randomized, double-blind, placebo-controlled, Phase III REGENCY (NCT04221477) trial assessing the efficacy and safety of obinutuzumab in active lupus nephritis. Primary and key secondary endpoints, as well as some exploratory analyses, are reported for obinutuzumab plus standard therapy and placebo plus standard therapy after 76 weeks of treatment.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 17 / Roche and Genentech
Characteristics and treatment patterns of patients with lupus nephritis: a retrospective claims database study in the USA
This retrospective, observational cohort study assessed first-line treatment patterns among newly diagnosed patients with lupus nephritis overall and by time period (before or on/after Jan 1, 2021), by prior use of any immunosuppressants and by race and ethnicity.

Sign up or login to unlock the full suite of MEDICALLY features

Nov 16 / Roche and Genentech
Obinutuzumab Benefits Patients With Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: a Post Hoc Analysis of a Phase II Trial
This post hoc analysis assessed the achievement of complete renal response (CRR) in participants with lupus nephritis from the Phase 2 NOBILITY trial (NCT02550652) using primary endpoint definitions from the ongoing Phase 3 REGENCY (NCT04221477) and completed BLISS-LN trials. In addition, this analysis evaluated the effect of proteinuria at baseline on achieving the REGENCY CRR.
Upcoming Congresses
Access to Roche and Genentech’s latest medical information
View related congresses

Ask a question or share feedback